Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03992456 · ClinicalTrials.gov registry record · Phase 2
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
A Phase 2 study of Metastatic Colorectal Carcinoma and Stage III Colorectal Cancer AJCC v8, sponsored by Academic and Community Cancer Research United.
- Active
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 18
- Study locations
NCT03992456 is a Phase 2 study of Metastatic Colorectal Carcinoma and Stage III Colorectal Cancer AJCC v8 that is active but no longer recruiting, run by Academic and Community Cancer Research United. The registered enrollment target is 12 participants, below the 88-participant average among 22 other Metastatic Colorectal Carcinoma trials with a reported enrollment target (86% lower). The trial reports 18 study locations across 13 states.
The verdict
NCT03992456, a Phase 2 study of Metastatic Colorectal Carcinoma and Stage III Colorectal Cancer AJCC v8, is active but no longer recruiting, sponsored by Academic and Community Cancer Research United.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 18
- Study locations
Study Summary
This phase II trial studies how well retreatment with panitumumab works compared to standard of care regorafenib or trifluridine and tipiracil hydrochloride (TAS-102) in treating patients with colorectal cancer that is negative for RAS wild-type colorectal cancer has spread to other places in the body (metastatic), and/or cannot be removed by surgery (unresectable), and is negative for resistance mutations in blood. Treatment with panitumumab may interfere with the ability of tumor cells to grow and spread. Some tumors need growth factors to keep growing. Growth factor antagonists, such as regorafenib, may interfere with the growth factor and stop the tumor from growing. Drugs used in chemotherapy, such as TAS-102, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving panitumumab may work better in treating patients with colorectal cancer than with the usual treatment of regorafenib or TAS-102.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- DRUG Regorafenib
- BIOLOGICAL Panitumumab
- DRUG Trifluridine and Tipiracil Hydrochloride
Study Locations (18)
California
- UC San Diego Moores Cancer Center - La Jolla
- USC / Norris Comprehensive Cancer Center - Los Angeles
- Cedars Sinai Medical Center - Los Angeles
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
- MedStar Washington Hospital Center - Washington D.C.
Arizona
- Mayo Clinic in Arizona - Scottsdale
Florida
- Mayo Clinic in Florida - Jacksonville
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Illinois
- University of Chicago Comprehensive Cancer Center - Chicago
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-04-24 |
| Est. Completion | 2024-10-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03992456
The ClinicalTrials.gov registry entry for NCT03992456 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 88-participant average among 22 other Metastatic Colorectal Carcinoma trials with a reported enrollment target (86% lower). The listed sponsor is Academic and Community Cancer Research United, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Metastatic Colorectal Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.
NCT03992456 reports 18 study locations spanning 13 distinct geographic areas - top geographies include California, Massachusetts, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT03992456 about?
NCT03992456 is a clinical study titled "Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer". This phase II trial studies how well retreatment with panitumumab works compared to standard of care regorafenib or trifluridine and tipiracil hydrochloride (TAS-102) in treating patients with colorectal cancer that is negative for RAS wild-type colorectal cancer has spread to other places in the bo...
What is the current status of trial NCT03992456?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2020-04-24. Estimated completion is 2024-10-07.
What conditions does trial NCT03992456 study?
This clinical trial studies the following conditions: Metastatic Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8.
What interventions are being tested in trial NCT03992456?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Regorafenib (DRUG), Panitumumab (BIOLOGICAL), Trifluridine and Tipiracil Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03992456?
This trial is sponsored by Academic and Community Cancer Research United, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03992456 being conducted?
This trial has 18 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
COMPLETED · Phase 2
-
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
RECRUITING · Phase 1
-
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
RECRUITING · NA
-
Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Metastatic Colorectal Carcinoma
All registered trials for this condition
Stage III Colorectal Cancer AJCC v8
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.